Better Therapeutics And Glooko Announce Partnership To Accelerate Adoption Of AspyreRx To Treat Type 2 Diabetes In The United States
Better Therapeutics Inc. (NASDAQ: BTTX) and Glooko, Inc. established a strategic alliance to include Better Therapeutics' AspyreRxTM digital behavioral treatment for type 2 diabetes (T2D) into Glooko's diabetes management platform. Better Therapeutics is a pioneer in the development of prescription digital therapeutics (PDTs) for the treatment of cardiometabolic disorders, whereas Glooko is a global leader in chronic condition management.
This agreement seeks to give healthcare providers in the United States who use the Glooko platform the capacity to discover appropriate AspyreRx patients, expedite prescriptions, and track patients throughout their treatment journey. Glooko's diabetes management solutions have already helped over 3.4 million diabetics in the United States and are used in approximately 5,000 clinics.
AspyreRx will be incorporated into the Glooko healthcare provider (HCP) platform in the United States, providing healthcare professionals with a new treatment option and enhancing the range of tools available for managing patient populations. The platform will identify patients who are ideal candidates for AspyreRx by leveraging Glooko's 'precision engagement' capabilities, facilitating the healthcare provider's capacity to deliver this novel medication.
Glooko CEO Russ Johannesson expressed excitement about the collaboration, saying, "We are very pleased to partner with Better Therapeutics to add AspyreRx to the Glooko platform." This collaboration will make a vital new treatment option available to healthcare practitioners in the Glooko network, allowing them to better manage their patient populations and improve health outcomes for T2D patients."
Better Therapeutics CEO Frank Karbe cited Glooko as a suitable partner for boosting AspyreRx adoption, stating the considerable overlap between providers using the Glooko platform and those identified as early adopters for AspyreRx. He also noted Glooko's precision engagement's potential to hasten access to AspyreRx for patients who potentially benefit from this novel new medication.
Better medicines specializes in the development of a revolutionary type of cognitive behavioral treatment (CBT) via prescription digital medicines to address underlying variables that contribute to or worsen cardiometabolic disorders. The patented platform of the company focuses on developing FDA-regulated, software-based treatments for T2D, heart disease, and other illnesses. Better Therapeutics' PDTs offer CBT with the goal of inducing changes in brain circuits, allowing for long-term behavioral changes and perhaps improving patient health while lowering healthcare expenditures. Better Therapeutics' clinically verified mobile applications are designed to be prescribed by clinicians and reimbursed in the same way that traditional medicines are.
In summary, Better Therapeutics and Glooko's collaboration is positioned to improve diabetes care by incorporating AspyreRx into the Glooko platform. This agreement takes advantage of Glooko's broad reach in assisting millions of people living with diabetes, giving healthcare providers a new and innovative treatment option to improve patient outcomes in the United States.
Comments
Post a Comment